Table 3.
Characteristic | Model 1b (Race/ethnicity only) Crude PR (95% CI) | Model 2b (Individual-level variables but not HIV testing site) Adjusted PR (95% CI) | Model 3b (Individual- level variables and HIV testing site type) Adjusted PR (95% CI) | Model 4b (Individual- and ZCTA-level variables and testing site type) Adjusted PR (95% CI) |
---|---|---|---|---|
Individual-level variables | ||||
Race/ethnicity | ||||
Non-Hispanic black | 1.75 (1.55–1.97) | 1.72 (1.52–1.94) | 1.66 (1.47–1.88) | 1.57 (1.38–1.78) |
Hispanic | 1.16 (1.00–1.33) | 1.24 (1.06–1.44) | 1.17 (1.00–1.36) | 1.14 (0.98–1.33) |
Non-Hispanic white | Referent | Referent | Referent | Referent |
Sex at birth | ||||
Male | 1.44 (1.27–1.64) | 1.30 (1.14–1.47) | 1.31 (1.15–1.48) | |
Female | Referent | Referent | Referent | |
Age group at diagnosis | ||||
13–19 years | Referent | Referent | Referent | |
20–39 years | 0.97 (0.82–1.16) | 1.01 (0.85–1.20) | 1.00 (0.85–1.19) | |
40–59 years | 0.71 (0.59–0.87) | 0.80 (0.66–0.97) | 0.79 (0.65–0.96) | |
60 years or older | 0.70 (0.55–0.90) | 0.87 (0.68–1.11) | 0.86 (0.67–1.09) | |
US- vs. foreign-born | ||||
US bornc | 1.23 (1.10–1.37) | 1.21 (1.09–1.35) | 1.21 (1.08–1.34) | |
Foreign born | Referent | Referent | Referent | |
Mode of HIV transmission | ||||
Heterosexual contact | Referent | Referent | Referent | |
Male-to-male sexual contact (MSM) | 0.68 (0.60–0.77) | 0.72 (0.64–0.81) | 0.73 (0.65–0.82) | |
Injection drug use (IDU)d | 1.12 (0.93–1.35) | 1.14 (0.94–1.38) | 1.14 (0.94–1.37) | |
Other/unknown | 1.70 (1.51–1.91) | 1.57 (1.40–1.76) | 1.58 (1.41–1.77) | |
AIDS diagnosis within 3 months of HIV diagnosis | ||||
Yes | Referent | Referent | Referent | |
No | 38.16 (21.76–66.91) | 33.10 (19.00–57.66) | 33.05 (18.98–57.54) | |
Year HIV diagnosed | ||||
2014 | Referent | Referent | Referent | |
2015 | 0.86 (0.79–0.94) | 0.87 (0.80–0.95) | 0.87 (0.80–0.95) | |
Type of HIV test site | ||||
Outpatient | Referent | Referent | ||
Hospitale | 1.04 (0.87–1.23) | 1.04 (0.87–1.23) | ||
Case management and counseling and testing site | 1.63 (1.45–1.83) | 1.62 (1.44–1.81) | ||
Blood bank/plasma center | 2.49 (2.23–2.79) | 2.45 (2.19–2.74) | ||
Otherf | 1.37 (1.17–1.61) | 1.36 (1.16–1.60) | ||
ZCTA-level variables | ||||
SES index, quartilesg | ||||
1 (lowest SES) | Referent | |||
2 | 0.91 (0.81–1.03) | |||
3 | 0.88 (0.76–1.02) | |||
4 (highest SES) | 0.90 (0.77–1.05) | |||
Non-Hispanic black density (% of total population) | ||||
<25% | Referent | |||
25-49% | 1.06 (0.93–1.20) | |||
≥50% | 1.08 (0.95–1.23) | |||
RUCA classification | ||||
Rural | 1.20 (0.92–1.56) | |||
Urban | Referent |
Abbreviations: AIDS: acquired immune deficiency syndrome; C & T: counseling and testing; HIV: human immunodeficiency virus; RUCA: Rural-Urban Commuting Area; SES: socioeconomic status; US: United States; ZCTA: ZIP code tabulation area.
Note:
Did not meet care initiation definition: within 3 months of HIV diagnosis a documented laboratory result (cluster of differentiation4 immune cell [CD4] count or viral load), medical visit, or antiretroviral prescription as ascertained through the Enhanced HIV/AIDS Reporting System, AIDS Drug Assistance Program database, or in the Florida Department of Health HIV services databases.
The Quasilikelihood under the Independence Model Criterion (QIC) was 10,576.77 for model 1; 9,702.52 for model 2, 9,524.39 for model 3 and 9,531.12 for model 4.
Category includes cases born in any of the 50 US states, District of Columbia, or any US dependency.
Includes cases with mode of transmission reported as injection drug use or injection drug use with male-to-male sexual contact.
Hospital includes any hospital department (e.g. inpatient, emergency department)
Other/unknown screening site includes laboratory, drug treatment center, other, and missing.
Quartiles of standardized SES scores for Florida ZCTAs.